Healthy Returns: Eli Lilly’s cholesterol pill impresses in mid-stage trial
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...
Zacks.com on MSN7h
LLY Oral Cholesterol Drug Lowers Lipoprotein Levels in Phase II Study
Eli Lilly LLY announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced lipoprotein(a) ...
News Medical9h
New research links sphingolipids to heart disease and atherosclerosis
Excess cholesterol is known to form artery-clogging plaques that can lead to stroke, arterial disease, heart attack, and more, making it the focus of many heart health campaigns.
Eli Lilly's Investigational Drug Cuts Sticky Cholesterol Levels By Almost 86%
Eli Lilly's muvalaplin Phase 2 trial showed significant Lp(a) reduction, meeting primary and secondary endpoints with ...
STAT18h
Two drugs look promising for lipoprotein(a), a common genetic risk factor for heart disease
At AHA, Phase 2 results from Eli Lilly and Silence Therapeutics are seen as signs of a "major new path" of cardiovascular ...